Background: Phosphodiesterase-4 (PDE4) inhibitors have potential utility as a new therapeutic approach to improving symptoms and pulmonary function in asthma and COPD. This study evaluated the efficacy and safety of MK-0359, a selective and potent oral PDE4 inhibitor, in chronic asthma. Methods: Adults (N Z 88) with !1 year asthma history and an FEV 1 50e80% predicted were randomized to double-blind treatment with MK-0359 (15 mg/day) or placebo for 14 days, then crossed-over to the other treatment for 14 days. The primary endpoint was the change from baseline in FEV 1 at the end of each 2-week treatment period. Secondary and other endpoints included the changes from baseline in Daytime asthma symptom score, Nighttime asthma symptom score, Total daily b-agonist use (puffs/day), AM and PM peak expiratory flow (PEF) and overall asthma-specific quality-of-life. Safety and tolerability were assessed by clinical adverse experiences. 
Introduction
Despite the availability of several controller agents, asthma remains poorly controlled in many patients, and its prevalence continues to be unacceptably high. 1, 2 Thus, there is much interest in exploring alternative therapeutic approaches that target further pathways mediating lower airway function. 3 Phosphodiesterase (PDE) consists of a family of enzymes that hydrolyze cAMP, an ubiquitous mediator that regulates several cellular processes. The enzymes PDE4A, PDE4B, and PDE4D are expressed in inflammatory cells such as T cells, B cells, eosinophils, neutrophils, and airway epithelial and endothelial cells. 4 Several studies in animal models and in patients with asthma or COPD have demonstrated that the selective inhibition of PDE4 produces relaxation of smooth muscle and inhibition of cellular inflammatory processes. 3e5 The PDE4 inhibitors roflumilast and cilomilast have been reported to improve pulmonary function and symptoms in asthma and COPD patients. Recently, the compound MK-0359 was reported to be a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma. 9 MK-0359 preferentially inhibited the hydrolysis of cAMP by PDE4A, 4B, and 4D, significantly reversed bronchoconstriction in ovalbumin-sensitized and challenged guinea pigs, and blocked late airway response in ascaris-sensitized and challenged sheep. 9 In previous Phase I studies, a range of doses of MK-0359 up to 20 mg in healthy subjects was generally well-tolerated (unpublished data). A 14-day, double-blind, placebo-controlled safety study of 12 patients (8 treated with MK-0359 15 mg/day and 4 with placebo) showed that the drug was generally well-tolerated. The frequencies of gastrointestinal adverse experiences of nausea, emesis (vomiting), loose stool, loss of appetite, and abdominal cramping in preliminary, blinded data were each 1/12 (8%).
Based on these studies, a 15-mg dose was expected to provide a level of systemic drug exposure (area under the curve of approximately 3367 nM h) less than the noobserved-effect-level (the highest dose at which no effects can be observed, a measure of chronic toxicity) for emesis seen in animal studies. Dose-dependent and sustained (up to 24 h) ex vivo inhibition of lipopolysaccharide-stimulated TNF-a, a surrogate marker for the anti-inflammatory activity of PDE4 inhibitors, was seen in a single-dose pharmacodynamic study evaluating doses up to 40 mg of MK-0359 in healthy subjects (unpublished data). Furthermore, in a multiple-dose study evaluating daily doses of 0.25 mg, 2.5 mg, 5 mg, 10 mg, and 15-mg MK-0359 in healthy subjects, the latter dose produced the greatest peak and trough levels of ex vivo inhibition of lipopolysaccharidestimulated TNF-a (unpublished data). For these reasons, we chose an MK-0359 dose of 15 mg/day for evaluating its efficacy on FEV 1 and other endpoints in patients with chronic asthma, and for evaluating its safety and tolerability.
Methods
This was a multicenter (26 study sites), randomized, placebo-controlled, double-blind, crossover Phase II study (Protocol 013) conducted between September 2002 and April 2003. Period I was a 14-day, single-blind, placebo runin period. Period II was a 14-day, double-blind, activetreatment period where patients were allocated according to a computer-generated, randomization schedule to either MK-0359 15 mg/day or placebo. Period III was a 13-day wash-out period. Period IV was a 14-day double-blind treatment period where patients were crossed-over to the other treatment.
Adult patients (N Z 88) with a clinical history of asthma symptoms for !1 year, an FEV 1 of 50e80% of predicted, airflow reversibility of !12%, and a minimum predetermined level of daytime asthma symptoms and of b-agonist use were enrolled. They were allowed the use of as-needed short-acting b-agonist during the study; approximately half the patients were allowed the use of inhaled corticosteroids (ICS) at a stable dose.
Baseline values were established in the placebo run-in period (Period I). The primary efficacy endpoint was the change from baseline in FEV 1 at the end of a once-daily dosing interval, assessed at the end of each 2-week treatment period (Periods II and IV). FEV 1 was also measured at 2 and 4 h after the first dose, and at 2 and 4 h after the last dose during the 2 weeks of treatment. Secondary endpoints recorded daily 10 were the changes from baseline in Daytime asthma symptom score (a 4-item questionnaire assessing frequency and level of symptoms and activity), Nighttime asthma symptoms score (assessing awakenings), Total daily b-agonist use (number of puffs), AM PEF, and PM PEF, each assessed as the average of the last 7 days of treatment. The changes from baseline in Asthma Quality of Life Questionnaire (AQLQ) domains (activity, emotion, symptoms, environment) 11 and in the average of all domains were assessed after 2 weeks of treatment.
Changes from baseline in FEV 1 were analyzed using an analysis of variance model that contained factors for sequence, patient within sequence, period, and treatment. Other efficacy measurements were analyzed using a similar model.
Safety and tolerability were assessed by clinical evaluations (physical examinations), adverse experience monitoring (including potential mechanism-based gastrointestinal effects, with colitis identified as an adverse experience of special interest), and laboratory safety tests.
The study was designed such that a sample size of 100 patients had approximately 80% power to detect (a Z 0.05, two-sided) a 0.12 L between-treatment difference in change from baseline in FEV 1 . However, because the study was prematurely terminated (as described below), the final sample size was smaller than planned.
The study was approved by an ethical review committee or institutional review board for each study site. Informed consent was obtained from each patient.
Results
Forty-two patients were randomized to the MK-0359/ placebo arm and 46 patients to the placebo/MK-0359 arm (Fig. 1) . Fifty-six patients completed the study; 21 patients discontinued. While this study was ongoing, MK-0359 failed to achieve an overall acceptable benefit/risk ratio in a concurrent study of COPD (Protocol 016). For this reason, a decision was made to halt the development of MK-0359 for chronic lower airway disease. Therefore, the present study was terminated, resulting in the discontinuation of a further 11 patients. Reasons for discontinuation of these 32 patients are listed in Fig. 1 .
Baseline characteristics were generally comparable between the two treatment sequences (Table 1) . Over the treatment period, statistically significant effects of MK-0359 over placebo were seen with the primary endpoint ( Table 2 ). Fig. 2 shows the mean change (L) from baseline in FEV 1 during the course of the study. Significant effects of MK-0359 over placebo were also seen with the other endpoints of Daytime and Nighttime asthma symptom scores, Total daily b-agonist use, AM and PM PEF, overall asthma-specific quality-of-life score, and total peripheral blood eosinophil counts (Table 2 ). There were no acute treatment effects immediately after dosing, as measured by FEV 1 at 2 and 4 h postdose (data not shown). There was no evidence that patients on ICS (N Z 30) had a consistently greater treatment effect than those not on ICS (N Z 58) in the endpoints studied. For instance, for the primary endpoint of FEV 1 , the difference between the treatment groups in percentage change from baseline was 0.4% in patients on ICS, and 5.9% in patients not on ICS.
The numbers of patients with clinical adverse experiences are summarized in Table 3 . Clinical adverse experiences occurred in 62.0% of patients while receiving MK-0359 and 40.3% while receiving placebo. Nineteen patients (24.1%) on MK-0359 and 8 patients (10.4%) on placebo reported gastrointestinal clinical adverse experiences. Serious clinical adverse experiences were reported in 3 patients while receiving MK-0359: abdominal pain (2) and diarrhea (2) . Four patients receiving MK-0359 were discontinued due to clinical adverse experiences determined by the investigator to be drug related: vomiting (1), loose stools (2), dizziness (3), paresthesia (1), and flushing (1).
Discussion
Reduction in airway inflammation and relief from bronchoconstriction are essential goals of current treatment guidelines for asthma. 12 The involvement of the PDE4 family of enzymes in cellular inflammation and bronchoconstriction offers a rationale for targeting them in asthma therapy. The promising efficacy of PDE4 inhibitors in airway disease has been reported by several investigators. Roflumilast produced dose-dependent improvement in FEV 1 and AM PEF in asthmatic patients, and both roflumilast and cilomilast attenuated exercise-induced bronchoconstriction. 4, 7 Cilomilast has, in general, shown an inconsistent effect on bronchodilation in COPD studies. 6 The results of the present study show that over a 14-day treatment period, MK-0359 (15 mg/day) improved airway function as measured by FEV 1 at the end of the dosing interval, as well as AM and PM PEF. The overall treatment effect was significant, although modest: the average improvement in change from baseline (MK-0359 minus placebo) in FEV 1 was about 3.5%, and the average improvements in AM and PM PEF were 1.8e2.4%.
Significant improvements in asthma symptoms throughout the day were seen, as measured by daytime symptoms (average improvement [MK-0359 minus placebo] in change from baseline was 9%) and nighttime symptoms. Total daily b-agonist use is a useful clinical measure of the control of symptoms, 12 and the administration of MK-0359 resulted in a greater control when compared to placebo (average improvement was 14.8%). Patients also reported improved asthma-specific quality-of-life with MK-0359: the total AQLQ score and the individual domains of symptoms and activity were significantly improved versus placebo. Taken together, these results are indicative of a significant 
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Placebo/MK-0359 N=46 Figure 1 Patient disposition. y Site terminated as described in Results. efficacy of MK-0359 in asthma. Furthermore, an antiinflammatory effect of MK-0359 was suggested by the reduction in blood eosinophil count, a marker of allergic airway inflammation. 13, 14 Nevertheless, these results must be interpreted with caution because the smaller sample size resulting from the early termination of the study may have reduced the possibility of showing significant effects in some of our endpoints. The clinical significance of our efficacy results in this Phase II study needs to be verified in a longer-term and larger clinical trial.
In asthma patients, the inflammatory mediator TNF-a is present in increased concentrations in mucosal biopsies and bronchoalveolar fluid and is expressed in increased amounts by airway mast cells; furthermore, recent studies have proposed a role for this cytokine in severe asthma. 15e17 PDE4 inhibition by MK-0359 in stimulated whole human blood has been shown to effectively inhibit the production of TNF-a. 9 It remains to be demonstrated if inhibition of TNF-a occurs in parallel with a demonstrated improvement in airflow and symptoms in asthmatics treated with MK-0359.
Several studies have called into question the utility of the currently available PDE4 inhibitors as a class because of their side effects. Headaches and gastrointestinal disturbances such as diarrhea, nausea and vomiting were some of the major side effects of roflumilast and cilomilast in clinical studies of asthma and COPD. 4, 3 In our study, an increase in the incidence of gastrointestinal adverse experiences was seen with MK-0359; as with other available PDE4 inhibitors, these side effects may limit the application of this compound in clinical practice. It has been suggested that the use of inhalation forms of PDE4 inhibitors may overcome such effects. 18 Furthermore, the therapeutic ratio with respect to nausea and vomiting may be a function of PDE4 subtype selectivity, and selective PDE4 inhibitors that target specific PDE4 enzymes (such as PDE4B) may alleviate adverse effects while still preserving the antiinflammatory effect of the inhibitor. 3 
Conclusion
Over a 14-day treatment period, the PDE4 inhibitor MK-0359 demonstrated significant, although modest, efficacy in asthmatic patients, as measured by improvements in lower airway function, symptoms, and rescue medication use. Nevertheless, its poor tolerability profile appears to limit its overall benefit as a new therapy in asthma. 
